Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Catasys changed company name to OnTrak months ago. Can Ihub please upgrade the symbol: OTRK
News: $CATS National Health Plan Expands Catasys' OnTrak-CI Program Across Their National Medicare Advantage Business
Company’s enrollment momentum continued through June Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI-powered and telehealth-enabled, virtualized outpatient healthcare treatment company, today announced a three-year contra...
Read the whole news CATS - National Health Plan Expands Catasys' OnTrak-CI Program Across Their National Medicare Advantage Business
Yes. But not medicine. Care coaches for at risk mental care patients with challenges like depression, anxiety, loneliness, etc. It’s these types of patients who typically are “care avoidant” and ultimately cost the healthcare system a disproportionate amount, so the Catasys approach is early AI assisted diagnosis and personal “tele” (then therapist) care to diminish their financial drag on the system by getting them help early.
What do they have available "tele medicine" as opposed to "face to face" services?
Both still out there
Yes. And they still have yet to announce a National deal.
Game changer.
Looks like quite the squeeze going on now...IMO
$CATS
Oh well. They report in two weeks. Maybe before then
The next 2 catalysts will be:
1) Curt becomes CEO
2) National deal with United Healthcare
I expect this before the end of Feb.
If so, we could see a rather large short squeeze...
News: $CATS Curt Medeiros, President of OPTUM Advanced Data and Analytics at UnitedHealth Group, Joins Catasys as President and Chief Operating Officer
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced the appointment of Mr. Curt Medeiros as President and Chief Operating Officer. Mr. Terren Peizer, Chairman and CEO of Catasy...
In case you are interested CATS - Curt Medeiros, President of OPTUM Advanced Data and Analytics at UnitedHealth Group, Joins Catasys as President and Chief Operating Officer
Third QTR results scheduled for November 13th.
https://finance.yahoo.com/news/catasys-schedules-2019-third-quarter-133000643.html
HUGE short position here - 40% of the float!
Earnings report is due next week. Should be very positive with 2020 forecasts slated!
http://shortsqueeze.com/?symbol=cats&submit=Short+Quote%E2%84%A2
Richard J Berman
Former Chairman of National Investment Managers
with $12 billion pension administration assets;
director of BioVie,Inc., Catasys, Inc., Advaxis, Inc., Cryoport Inc.
and Immuron Ltd. Previously started the M&A and
Leveraged Buyout Departments for Bankers Trust
Company.
https://www.biovieinc.com/wp-content/uploads/2019/10/BioVie-Corp-Presentation_website_Oct-2019.pdf <<< sleeping GEM
Agree. CATS seems well positioned to meet these conservative revenue goals. Hopefully the market begins to agree with this statement and we once again see a climb into the 20’s.
$90 million in REVs next year!
"Catasys (CATS) had some pretty interesting guarantees in their loan documents with Goldman Sachs. First off, they have (and this is written in the loan docs) guaranteed that they will do $90 million in revenue in 2020. My guess is that number could very well be where initial guidance for next year comes in, when it’s announced in November. Guidance of $90M will allow CATS to meet the street and have them raise numbers every quarter, which is the Company’s unspoken goal. Eventually, I suspect they come in at around $120M for the year, if not higher.
Secondly, CATS also guaranteed that, in the 12 months for which books had closed, prior to the GS financing, revenue was at least $29M. This means they are on a pace for around $10M in the third quarter, which should mean their target of $35M remains doable. These two guarantees should cause the large short position to reconsider their stance, one would think. But, so far they have yet to blink."
https://tailwindsresearch.com/2019/10/keeping-calm-in-stresa/
I dig the CATS .
BioVie (BIVI), one of CATS' Founder, CEO and Chairman Terren Peizer's portfolio of companies is debuting in the Nasdaq Exchange tomorrow!
Will Slattery
Vice President
Listing Qualifications
August 9, 2019
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Division of Corporation Finance:
This is to certify that on August 2, 2019, The Nasdaq Stock Market (the "Exchange") received from BioVie Inc.
(the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following
securities:
Class A common Stock, par value $.0001 per share
We further certify that the securities described above have been approved by the Exchange for listing and
registration upon official notice of issuance.
We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with
effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.
Sincerely
https://www.sec.gov/Archives/edgar/data/1580149/000135445719000410/8A_Cert_BIVI.pdf
Mr. Terren Peizer dubbed " The Zelig of Wall Street"
>>> BioVie Receives $3.2 Million Equity Investment <<<
On July 3, 2018, BioVie Inc. (OTCQB: BIVI) executed an agreement with Acuitas Group Holdings, LLC (“Acuitas”) and certain other investors to purchase $3.2 million of the Company’s Series A Preferred Stock, which was subsequently converted into approximately 213 million common shares. Acuitas has an option to fund up to an additional $3 million in one year on the same terms if certain other funding opportunities do not materialize. Additionally, Terren Peizer joined the board of the Company and assume the role of Chairman & Chief Executive Officer, with Jonathan Adams becoming President and Chief Operating Officer.
Mr. Peizer is an entrepreneur, investor, and financier with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a leader in behavioral and mental health management services. He has also served as the Company’s Chairman of the Board of Directors and CEO since the Company’s inception in 2004. Mr. Peizer also is the Founder, Chairman and CEO of NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. NeurMedix’s lead compound NE3107 has shown efficacy in 11 pre-clinical and 6 human studies. These studies resulted in publications in peer-reviewed journals. Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal holding company that is the owner of all of his portfolio company interests, including Catasys, Inc. Through Acuitas, Mr. Peizer also owns Crede Capital Group, LLC, an industry leader in investing in micro and small capitalization equities, having invested over $1.2 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder, and has held various senior executive positions with several other publicly-traded growth companies, including Chairman of internationally renowned Cray, Inc., the industry’s leading supercomputer company. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in finance from The Wharton School of Finance and Commerce.
Raised in Beachwood, Ohio, a suburb of Cleveland, Peizer has been the largest beneficial stockholder and has held various senior executive positions within several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs , First Boston and Drexel Burnham Lambert . Mr. Peizer received his B.S.E. in Finance from The Wharton School of Finance and Commerce.
You can follow more of Terren at his personal site:
http://terrenpeizer.com/
News: $CATS Sector Declining Stock- Catasys, Inc. (NASDAQ:CATS)
Catasys, Inc. (NASDAQ:CATS) reached at $15.74 price level during last trade its distance from 20 days simple moving average was -11.18%, and its di...
Got this from Sector Declining Stock- Catasys, Inc. (NASDAQ:CATS)
News: $CATS Catasys Schedules 2019 Second Quarter Financial Results Conference Call for August 14, 2019
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its second quarter ended June 30, 2019, after the closing of the stock market...
Find out more Catasys Schedules 2019 Second Quarter Financial Results Conference Call for August 14, 2019
CATS now included in Russell 3000 and 2000 indexes!
https://ih.advfn.com/stock-market/NASDAQ/catasys-inc-CATS/stock-news/80242304/catasys-announces-addition-to-russell-3000-and-20
CAT$ marking new highs!!!
News: $CATS Catasys to Present at the B. Riley FBR Institutional Investor Conference on Wednesday, May 22, 2019
Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company’s Chairman and Chief Executive Officer, will present at the B. Riley FBR Institutional Inv...
Got this from https://marketwirenews.com/news-releases/catasys-to-present-at-the-b-riley-fbr-institutional-investor-conference-on-wednesday-may-22-2019-8216610.html
News: $CATS Catasys Announces Partnership with Circulation and Lyft
Groundbreaking Relationship Expands Catasys’ Ability to Address Social Determinants of Health Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced a strategic partnership w...
Got this from https://marketwirenews.com/news-releases/catasys-announces-partnership-with-circulation-and-lyft-8142486.html
News: $CATS Catasys Expands OnTrak-C Solution with Leading National Health Plan
Catasys, Inc. (NASDAQ:CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it has expanded its OnTrak-C solution with one of the nation's leading health insurance providers. Eligible Medicaid members in T...
In case you are interested https://marketwirenews.com/news-releases/catasys-expands-ontrak-c-solution-with-leading-national-health-plan-8131948.html
CATS & BIVI will present in the upcoming ThinkEquity Conference on May 2 in New York City.
CATS https://finance.yahoo.com/news/catasys-present-thinkequity-conference-may-123000322.html
BIVI https://finance.yahoo.com/news/biovie-present-thinkequity-conference-nyc-110000827.html
Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to participate in the ThinkEquity Conference on May 2, 2019 in New York City. This event is dedicated to connecting small and micro-cap companies with high-level institutional and retail investors. Management will hold one-on-one meetings with investors during the conference.
BioVie, An Undiscovered Gem by Tailwinds Research Group
People who are good at what they do consistently outperform. This is true of many things like sports, entertainment and business. People like Roger Federer and Steve Jobs have consistently outperformed the competition. It is also true of investing where smart people develop track records over time. It is, generally speaking, very rewarding to follow successful investors, like a Warren Buffet, tracking their investments and participating in them when possible.
Tailwinds has developed our strong track record by finding underfollowed stocks that are off the radar screen of most investors; these are, shall we say, “undiscovered gems”. Our discovery of opportunities is frequently accomplished through sourcing ideas from our investor network. That network includes Terren Peizer.
Terren has developed a long-term track record of success running his Acuitas Group fund. He also is the CEO of Catasys, a company in which he has invested substantial personal funds. Catasys also happens to be our largest investment and a big winner for Tailwinds. Thus, it was certainly noteworthy for us when Terren invested millions of dollars to take majority control of BioVie, Inc. (BIVI).
Terren suggested that Tailwinds take a look at BioVie. After researching them, it has become readily apparent that this company falls into the category of undiscovered gems. Thus, we have established a position in the stock and are initiating coverage on it at Tailwinds.......https://tailwindsresearch.com/2019/04/biovie-an-undiscovered-gem/
BioVie is unbelievably way under-the-radar. It is the most undervalued NASH related stock you can find in the market. Mr. Terren Peizer saw the great potential of this company, not to mention Mallinckrodt's (MNK) interest on BioVie's Technology Platform, thus initiating a IP patent challenge with the USPTO which I think the deciding factor that led him to embark in this microcap company. Considering his profile, I believe BioVie is in good hands. All this in my opinion only.
News: $CATS Catasys Reports 2018 Fourth Quarter and Year-end Financial Results
Q4 2018 Record Revenue of $5.6 Million, up 85.3% Year over Year and Up 28.7% from Q3 2018 YE 2018 Record Revenue of $15.2 Million, Up 96.7% from YE 2017 Outreach Pool of Eligible Members Increased to approximately 75,000 Members at March 1, 2019 (up 97% from 38,000 at Q3 2018)...
Find out more https://marketwirenews.com/news-releases/catasys-reports-2018-fourth-quarter-and-year-end-financial-results-7848194.html
News: $CATS Catasys Announces Expansion of Debt Financing Agreement to $15 Million; Proceeds to be Utilized to Support Accelerating Growth
Catasys, Inc. (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, announced today that it has entered into an amendment and expansion of its previously announced financing of a receivable facility agreement and term loan (see: Catasys Attracts $10 Million in Debt Financi...
Got this from https://marketwirenews.com/news-releases/catasys-announces-expansion-of-debt-financing-agreement-to-15-million-proceeds-to-be-utilized-to-support-accelerating-growth-7847046.html
BioVie (otcqb:BIVI) TERREN PEIZER, CEO,Board Chairman
Mr. Peizer is an entrepreneur and an investor with a particular interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a publicly traded leader in behavioral and mental health management services. He has also served as the Company’s Chairman of the Board of Directors and CEO since the Company’s inception in 2004. Catasys has contracted with 7 of the 8 largest health plans in the USA that covers 70% of the country's population. Mr. Peizer also is the Founder, Chairman and CEO of NeurMedix, Inc., a biotechnology company with a focus on inflammatory, neurological and neuro-degenerative diseases. NeurMedix’s lead compound NE3107 has shown efficacy in 11 pre-clinical and 6 human studies. These studies resulted in publications in peer-reviewed journals. Mr. Peizer is also the Chairman, CEO and majority shareholder of publicly traded BioVie, Inc. which is the industry leader in the development of two orphan drug candidates for the treatment of the rare liver diseases Ascites and HRS. Mr. Peizer is Chairman of Acuitas Group Holdings, LLC, his personal holding company that is the owner of all of his portfolio company interests, including Catasys, Inc. Through Acuitas, Mr. Peizer also owns Acuitas Capital Group, LLC, an industry leader in investing in publicly traded micro and small capitalization equities, having invested over $1.5 billion directly into portfolio companies. Mr. Peizer has been the largest beneficial shareholder, and has held various senior executive positions with several other publicly-traded growth companies, including Chairman of internationally renowned Cray, Inc., the industry’s leading supercomputer company. Mr. Peizer has a background in finance and capital markets having previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham Lambert. He received his B.S.E. in finance from The Wharton School.
getting there!!!
Catasys is about to explode!!! I have been a shareholder of CATS/Hythiam for years. Within the year, we will be over $12.00/share! This will be a blockbuster! With all the press about the Opioid Crisis Epidemic, and Catasys being at the forefront , We will all be rich soon. I am hoping that one of the MAJOR Health Insurance companies will buy Catasys. Watch and learn. I will be back soon with more updates. Thank You to all my fellow Catasys Believers!
looks like we've churned through the secondary and are now ready to get back to the $7-$9 range soon
What do the financials look like that were posted today?
How do you get a copy of the analyst reports? Been looking for reaction to the recent stock price action. Any defense coming from them?
If you read the SEC filings, or the two analysis reports, there's major insider buying. And that includes major buying by the CEO. Do you think he knows something something good is about to happen? He spent a million dollars on his last purchase a few weeks ago. If you think about it, he didn't have to do that. Also, in one of the two analysis report, the overall score was raised within their point system because of the insider buying. In my opinion, these guys are loading up because good things are about to happen.
I know that gap down after that last fund raiser will get filled. That was mostly artificially created. Thus shortly we will pick up where we last left off. That is at the pre-split $2.00 price which would now be $12.00. And nothing has changed regarding the great business model, fast expansion, and huge earnings growing. That's why the analyst have us going to $19.50. And because we're now on Nasdaq, there's no holding us back, and as we expand and grow, the skies the limit beyond $19.50.
After reverse split, my average is now 7.25 per share. I hope that their earnings looks fantastic. Otherwise, this is a bust. Nice to see the CEO is putting up some cash. Shows that he believes!
What is happening with this? Down 10%+
Could be very nice play. Conference on 2nd of May . Could run very nicely.Reverse split play + lowfloater less than 3mln shares in float. Nice article about company http://nasdaqrunners.blogspot.ru/2017/04/cats-big-upside-runner.html
CATSD moved from the OTC to the Nasdaq:
http://otce.finra.org/DLDeletions
yes NASDAQ approved it last night
Deal priced at .80 pre split....yuck
Followers
|
22
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
438
|
Created
|
12/09/07
|
Type
|
Free
|
Moderators |
Hythiam, Inc. provides through its Catasys® subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys Substance Dependence Program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary Prometa® Treatment Program for alcoholism and stimulant dependence. The Prometa Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers.
Providing specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers.
For more info CatasysHealth.com
Hythiam Leadership Team | ||||||||||||||||||||||||
Terren S. Peizer Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce. Rick A. Anderson Richard A. Anderson has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006. Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara. Peter Donato Peter Donato has nearly 20 years of progressive financial management experience in large, publicly traded companies as well as small, entrepreneurial companies. He began his career in public accounting with Ernst & Young, and most recently served as CFO of Iris International, a NASDAQ traded medical diagnostics equipment manufacturer, and CFO of Gamma Medica-Ideas, an early stage medical imaging company. He is credited for establishing a strong and timely reporting structure, improved control environment, recruiting and retaining strong accounting, finance and IT teams, as well as developing and maintaining strong relationships with external stakeholders including: investors, coverage analysts, bankers, insurance brokers and auditors. He has held positions with increasing responsibilities at General Motors, Honda, Scotts-Miracle Gro, and Accellent. Mr. Donato graduated from The Ohio State University with a BS in Business Administration and earned an MBA from the University of Akron. Gary Ingenito, MD, PhD Dr. Ingenito is responsible for preclinical and clinical scientific research and development. He is a member of the senior executive management team, providing strategic direction for future clinical trials, clinical product development, creation of expanded patient treatment algorithms, data analysis and reporting. Dr. Ingenito previously held executive positions at Angiotech, SFBC International, Otsuka Pharmaceuticals, Corning-Besselaar, and Novartis. A neurologist, Dr. Ingenito
Mr. McLane is responsible for the overall sales and marketing efforts of the company, encompassing customer acquisition, marketing strategy, market research, member outreach and account management. Prior to joining the company he led the marketing activities for Magellan Health Services and founded Optimized Benefits, Inc., a health benefits company that replaced the one-size-fits-all HMO, PPO and CDHP plans with “Life Stage” plans which address the different needs of employees at various stages of their lives. He also led strategy development and product development for CIGNA and ran consumer products businesses for Procter & Gamble, Campbell Soup and Nabisco. Mr. McLane earned a Bachelor of Science degree from The Wharton School of the University of Pennsylvania with majors in accounting and decision science, and a Masters of Business Administration from Cornell University with concentrations in management and organizational behavior.
Dr. Weinstein leads the clinical initiatives for the development of clinical products and provides medical leadership for the business development, marketing and site management departments. Dr. Weinstein also serves as the primary clinical liaison to licensees, physician groups, corporate affiliations, managed care organizations, insurers and external affairs. Prior to Catasys, Dr. Weinstein held positions at PacifiCare Behavioral Health/United Behavioral Health, Magellan Behavioral Health and the Chemical Dependence Unit at St. Elizabeth’s Hospital in Chicago. He has also worked in private practice providing individual and group diagnostic and psychotherapeutic services, as well as family therapy. Dr. Weinstein received his M.D. from the Ross University School of Medicine, and completed his internship and residency in psychiatry at Michael Reese Hospital and Medical Center in Chicago. |
Hythiam Board of Directors | ||
Terren S. Peizer Chairman and Chief Executive Officer Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce. Rick A. Anderson President and Chief Operating Officer Rick A. Anderson, has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006. Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara. Andrea Grubb Barthwell, M.D., F.A.S.A.M. Andrea Grubb Barthwell, M.D., F.A.S.A.M., is the founder and Chief Executive Officer of the global health care and policy-consulting firm EMGlobal LLC and Director at Two Dreams Outer Banks Treatment Center. President George W. Bush nominated Dr. Barthwell in December 2001 to serve as Deputy Director for Demand Reduction in the Office of National Drug Control Policy (ONDCP). The United States Senate confirmed her nomination on January 28, 2002. As a member of the President's sub-cabinet, Dr. Barthwell was a principal advisor in the Executive Office of the President (EOP) on policies aimed at reducing the demand for illicit drugs. Dr. Barthwell received a Bachelor of Arts degree in Psychology from Wesleyan University, where she serves on the Board of Trustees, and a Doctor of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. Dr. Barthwell served as President of the Encounter Medical Group (EMG, an affiliate of EMGlobal), was a founding member of the Chicago Area AIDS Task Force, hosted a weekly local cable show on AIDS, and is a past president of the American Society of Addiction Medicine. Dr. Barthwell received the Betty Ford Award, given by the Association for Medical Education and Research in Substance Abuse and has been named by her peers as one of the "Best Doctors in America" in addiction medicine. Marc G. Cummins Marc G. Cummins is a managing partner of Prime Capital, LLC, a private investment firm focused on consumer companies. Prior to founding Prime Capital, Mr. Cummins was managing partner of Catterton Partners, a private equity investor in consumer products and service companies with more than $1 billion of assets under management. Prior to joining Catterton in 1998, Mr. Cummins spent fourteen years at Donaldson, Lufkin & Jenrette Securities Corporation where he was managing director of the Consumer Products and Specialty Distribution Group, and was also involved in leveraged buyouts, private equity and high yield financings. Mr. Cummins received a B.A. in Economics, magna cum laude, from Middlebury College, where he was honored as a Middlebury College Scholar and is a member of Phi Beta Kappa. He also received an M.B.A. in Finance with honors from The Wharton School at University of Pennsylvania. Jay A. Wolf Jay A. Wolf has served as a director since June 2008. He is the founder and principal of Wolf Capital LP an investment advisory firm he formed in October 2009 to focus on small cap public companies. From November 2003 until September 2009, Mr. Wolf was a partner at Trinad Capital LLC, an activist hedge fund focused on micro-cap public companies. During his work at Trinad, Mr. Wolf assisted distressed and early stage public companies through active board participation, the assembly of management teams and business and financial strategies. Prior to his work at Trinad, Mr. Wolf served as executive vice president of Corporate Development for Wolf Group Integrated Communications Ltd. Prior to that, Mr. Wolf worked at Canadian Corporate Funding, Ltd., a Toronto-based merchant bank as an analyst in the firm’s senior debt department and subsequently for Trillium Growth Capital, the firm’s venture capital fund. Mr. Wolf currently also sits on the boards of Xcorporeal, Inc. (XCR), Zoo Entertainment, Inc. (ZOOE) and NorthStar Systems, Inc. Mr. Wolf is also a member of the board of governors at Cedars-Sinai Hospital. He is a former director of Asianada, Inc., ProLink Holdings Corp., Mandalay Media, Inc., Atrinsic, Inc., Shells Seafood Restaurants, Inc., Optio Software, Inc., Xcorporeal Operations, Inc., Zane Acquisition I, Inc., Zane Acquisition II, Inc., Starvox Communications, Inc. and Noble Medical Technologies, Inc. Mr. Wolf received his B.A from Dalhousie University. Mr. Wolf was chief operating officer and chief financial officer of Starvox Communications, Inc. from March 2005 to March 2007. On March 26, 2008, StarVox Communications, Inc. filed a voluntary petition for liquidation under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of California, San Jose. Shells Seafood Restaurants, Inc., a company for which Mr. Wolf formerly served as a director, filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division, on September 2, 2008. Mr. Wolf’s broad range of investment and operations experience, which includes senior and subordinated debt lending, private equity and venture capital investments, mergers and acquisitions advisory work and public equity investments, equip him with the qualifications and skills to serve on our Board of Directors. |
Form Type | Received | Period Ending | Size | Report |
---|---|---|---|---|
POS AM | Oct 1, 2010 | 49.2 KB | PDF RTF HTML XLS | |
POS AM | Oct 1, 2010 | 48.5 KB | PDF RTF HTML XLS | |
AW | Sept 28, 2010 | 12.6 KB | PDF RTF HTML | |
AW | Sept 28, 2010 | 12.6 KB | PDF RTF HTML | |
POS EX | Sept 21, 2010 | 48.6 KB | PDF RTF HTML XLS | |
POS EX | Sept 21, 2010 | 49.4 KB | PDF RTF HTML XLS | |
3 | Sept 3, 2010 | Aug 25, 2010 | 4.3 KB | PDF RTF HTML XLS |
8-K | Aug 27, 2010 | Aug 25, 2010 | 38.5 KB | PDF RTF HTML XLS |
10-Q | Aug 16, 2010 | Jun 30, 2010 | 1.2 MB | PDF RTF HTML XLS |
8-K | Jul 7, 2010 | Jul 7, 2010 | 18.8 KB | PDF RTF HTML XLS |
Shares Outstanding | 55,154,688 | a/o Apr 28, 2009 |
American Stock Transfer & Trust Company |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |